SOPHARMA AD - Notification for initiation of acquisition transaction

Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:

1. SFA_Acquisition_Initiation_04102024_espi.pdfNotification for initiation of acquisition transaction
   

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 112 / 2024

Date of issue: 2024-10-04

Short name of the issuer

SOPHARMA AD

Subject

Notification for initiation of acquisition transaction

Official market - legal basis

art. 56. 1. 2 of Act on Public Offering.

Unofficial market - legal basis

Contents of the report:

“Sopharma” AD (the Company, SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that following its growth strategy and its goal of becoming a stronger regional player, the Company initiates a transaction for acquisition of a pharmaceutical product portfolio consisting of both CHC and prescription products in the following therapeutic areas: Sex hormones and modulators of the genital system, Urologicals and Antivirals for systemic use. The acquisition totals 68 marketing authorizations with 14 well-known brands in 10 of the traditional markets of the Company.

Annexes

File Description

SFA_Acquisition_Initiation_04102024_espi.pdfSFA_Acquisition_Initiation_04102024_espi.pdf Notification for initiation of acquisition transaction

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD Farmaceutyczny (far)

(short name of the issuer) (sector according to clasification of the WSE in Warsow)

1220 Sofia

(post code) (city)

IlienskoShosse 16

(street) (number)

[phone] [phone]

(phone number) (fax)

(e-mail) (web site)

nd

(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Date Name Position / Function Signature

2024-10-04 Ognian Donev Executive Director